naratuximab emtansine (Debio 1562)
naratuximab emtansine (Debio 1562), an anti-CD37 antibody-drug conjugate (ADC), is a potential new treatment for patients with B-cell malignancies, such as non-Hodgkin lymphomas (NHL). naratuximab emtansine (Debio 1562) demonstrated evidence of anti-cancer activity in NHL in a Phase 1 monotherapy trial and successfully completed a safety lead-in study in combination with Rituxan®. The product is currently in phase IIb in NHL and particularly in relapsed/refractory diffuse large-cell B-cell lymphoma (R/R DLBCL) for which it benefits from Orphan Drug status.
May 24, 2017
Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen
April 16, 2018
Development of novel preclinical models of secondary resistance to the anti-CD37 antibody drug conjugate (ADC) IMGN529/DEBIO1562 in diffuse large B-cell…